These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26820829)

  • 1. [Anti-platelets without a bleeding risk: novel targets and strategies].
    Schaff M; Gachet C; Mangin PH
    Biol Aujourdhui; 2015; 209(3):211-28. PubMed ID: 26820829
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-glycoprotein VI treatment severely compromises hemostasis in mice with reduced alpha2beta1 levels or concomitant aspirin therapy.
    Grüner S; Prostredna M; Aktas B; Moers A; Schulte V; Krieg T; Offermanns S; Eckes B; Nieswandt B
    Circulation; 2004 Nov; 110(18):2946-51. PubMed ID: 15505105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current and future antiplatelet therapies: emphasis on preserving haemostasis.
    McFadyen JD; Schaff M; Peter K
    Nat Rev Cardiol; 2018 Mar; 15(3):181-191. PubMed ID: 29297508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a novel function-blocking antibody targeted against the platelet P2Y1 receptor.
    Karim ZA; Vemana HP; Alshbool FZ; Lin OA; Alshehri AM; Javaherizadeh P; Paez Espinosa EV; Khasawneh FT
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):637-44. PubMed ID: 25593131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future Antithrombotic Therapies in Cardiology.
    Bäuml M; Hilgendorf I
    Hamostaseologie; 2018 Nov; 38(4):236-239. PubMed ID: 30267387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The search for new antithrombotic mechanisms and therapies that may spare hemostasis.
    Plow EF; Wang Y; Simon DI
    Blood; 2018 Apr; 131(17):1899-1902. PubMed ID: 29467183
    [TBL] [Abstract][Full Text] [Related]  

  • 7. From Patients to Platelets and Back Again: Pharmacological Approaches to Glycoprotein VI, a Thrilling Antithrombotic Target with Minor Bleeding Risks.
    Martins Lima A; Martins Cavaco AC; Fraga-Silva RA; Eble JA; Stergiopulos N
    Thromb Haemost; 2019 Nov; 119(11):1720-1739. PubMed ID: 31564053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current antithrombotic agents for acute coronary syndromes: focus on bleeding risk.
    Bassand JP
    Int J Cardiol; 2013 Feb; 163(1):5-18. PubMed ID: 22100180
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response variability to P2Y12 receptor inhibitors: expectations and reality.
    Siller-Matula JM; Trenk D; Schrör K; Gawaz M; Kristensen SD; Storey RF; Huber K;
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1111-28. PubMed ID: 24262612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet GPIb complex as a target for anti-thrombotic drug development.
    Clemetson KJ; Clemetson JM
    Thromb Haemost; 2008 Mar; 99(3):473-9. PubMed ID: 18327394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting integrin and integrin signaling in treating thrombosis.
    Estevez B; Shen B; Du X
    Arterioscler Thromb Vasc Biol; 2015 Jan; 35(1):24-9. PubMed ID: 25256236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-thrombotic effects and bleeding risk of AJvW-2, a monoclonal antibody against human von Willebrand factor.
    Kageyama S; Yamamoto H; Nagano M; Arisaka H; Kayahara T; Yoshimoto R
    Br J Pharmacol; 1997 Sep; 122(1):165-71. PubMed ID: 9298543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changing trends in anti-coagulant therapies. Are heparins and oral anti-coagulants challenged?
    Fareed J; Iqbal O; Cunanan J; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
    Int Angiol; 2008 Jun; 27(3):176-92. PubMed ID: 18506123
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel antiplatelet activity of protocatechuic acid through the inhibition of high shear stress-induced platelet aggregation.
    Kim K; Bae ON; Lim KM; Noh JY; Kang S; Chung KY; Chung JH
    J Pharmacol Exp Ther; 2012 Dec; 343(3):704-11. PubMed ID: 22984226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Thrombosis and new antithrombotic agents].
    Drouet L; Mahé I; Le Gal G; Righini M; Quéré I
    Rev Med Interne; 2011 Dec; 32 Suppl 2():S236-40. PubMed ID: 22041519
    [No Abstract]   [Full Text] [Related]  

  • 16. Mechanisms of platelet activation: need for new strategies to protect against platelet-mediated atherothrombosis.
    Jennings LK
    Thromb Haemost; 2009 Aug; 102(2):248-57. PubMed ID: 19652875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Future innovations in anti-platelet therapies.
    Barrett NE; Holbrook L; Jones S; Kaiser WJ; Moraes LA; Rana R; Sage T; Stanley RG; Tucker KL; Wright B; Gibbins JM
    Br J Pharmacol; 2008 Jul; 154(5):918-39. PubMed ID: 18587441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting glycoprotein VI and the immunoreceptor tyrosine-based activation motif signaling pathway.
    Stegner D; Haining EJ; Nieswandt B
    Arterioscler Thromb Vasc Biol; 2014 Aug; 34(8):1615-20. PubMed ID: 24925975
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New therapeutic approaches to combat arterial thrombosis: better drugs for old targets, novel targets, and future prospects.
    Choi J; Kermode JC
    Mol Interv; 2011 Apr; 11(2):111-23. PubMed ID: 21540471
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel therapeutic agents in the management of hemorrhage and thrombosis.
    Kempton CL; Harvey RD; Roberts HR
    Cardiovasc Hematol Agents Med Chem; 2006 Oct; 4(4):319-34. PubMed ID: 17073609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.